



Syndax Pharmaceuticals, Inc.  
 Investor Relations Department  
 35 Gatehouse Drive  
 Building D, Floor 3  
 Waltham, MA 02451  
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: SNDX**

Last Trade:	8.60
Trade Time:	10:47 AM ET 12.15.17
Change:	-0.40  (-4.444%)
Day Range	8.55 - 9.02
52-Week Range	6.31 - 15.70
Volume	81,693

Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- 11.11.17 [Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting](#)
- 11.07.17 [Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update](#)
- 11.07.17 [Syndax to Present at the SITC 32nd Annual Scientific Meeting](#)
- 10.31.17 [Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017](#)
- 10.17.17 [Syndax Announces \\$25 Million Registered Direct Offering of Common Stock](#)

**Financial Information** [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 11.08.17 [Quarterly Report \(10-Q\)](#)
- 08.10.17 [Quarterly Report \(10-Q\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)